A multicenter cohort study in the Journal of Ovarian Research reports sustained patient‑reported benefits for niraparib as long-term maintenance in platinum‑sensitive recurrent ovarian cancer. Researchers analyzed PROs to assess quality-of-life tradeoffs alongside clinical outcomes. The analysis finds durable symptom control and tolerability in many patients on extended niraparib, supporting its role in maintenance regimens and informing clinician–patient discussions about long-term therapy strategies.